

Financial Information

Consolidated Balance Sheets

(Thousands of yen)

	September 30, 2009	March 31, 2010
ASSETS		
CURRENT ASSETS		
Cash and time deposits	6,607,331	6,819,488
Notes and accounts receivable	5,211,905	6,120,494
Inventories and products	231,824	287,226
Works in progress	253,598	310,349
Others	1,140,119	1,260,436
Allowance for doubtful accounts	(2,108)	(2,870)
Total current assets	13,442,670	14,795,124
FIXED ASSETS		
Tangible Assets	445,165	548,902
Intangible Assets	364,189	967,961
Investments and other assets		
Investment securities	881,700	714,956
Deposits	1,012,144	1,105,801
Others	1,160,990	1,167,976
Total investments and other assets	3,054,836	2,988,734
Total fixed assets	3,864,190	4,505,597
TOTAL ASSETS	17,306,861	19,300,722

(Thousands of yen)

	September 30, 2009	March 31, 2010
LIABILITIES		
CURRENT LIABILITIES		
Accounts payable	204,226	301,188
Short-term debt	150,000	200,000
Current portion of long-term debt	200,000	100,000
Income taxes payable	944,772	1,068,161
Provision for bonuses	1,145,169	1,050,252
Provision for loss on order received	75,650	47,600
Others	1,899,275	2,152,540
Total current liabilities	4,619,093	4,919,742
LONG-TERM LIABILITIES		
Provision for employees' retirement benefits	307,137	346,168
Provision for directors' retirement benefits	247,397	258,329
Others	25,378	47,380
Total long-term liabilities	579,912	651,879
TOTAL LIABILITIES	5,199,006	5,571,621
NET ASSETS		
Shareholders' equity		
Common stock	1,875,251	1,875,251
Additional paid-in capital	1,825,431	1,825,431
Retained earnings	7,657,862	8,664,850
Common stock for treasury	(321,437)	(321,437)
Total shareholders' equity	11,037,108	12,044,096
Valuation and translation adjustments		
Unrealized gain (or loss) on available-for-sale securities	(39,782)	(60,034)
Deferred gain (or loss) on hedges	(2)	—
Foreign currency translation adjustments	(65,647)	(32,110)
Total valuation and translation adjustments	(105,431)	(92,145)
Share option in consolidated subsidiary	—	6,528
Minority interests	1,176,178	1,770,621
TOTAL NET ASSETS	12,107,854	13,729,100
TOTAL LIABILITIES AND NET ASSETS	17,306,861	19,300,722

Consolidated Statements of Income

(Thousands of yen)

	Second quarter ended March 31, 2009	Second quarter ended March 31, 2010
NET SALES	11,687,577	14,516,843
COST OF SALES	7,966,361	9,735,533
Gross profit	3,721,215	4,781,310
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	1,754,850	2,337,616
Operating income	1,966,364	2,443,694
OTHER INCOME (EXPENSES)		
Interest income	15,841	11,250
Interest expenses	(5,519)	(5,279)
Foreign exchange gain or loss (loss)	(7,063)	(29,608)
Gain on cancellation of insurance	—	14,682
Gain on sale of investments in securities	8,320	—
Gain on change in equity by merger of consolidated subsidiary	—	34,961
Refund of insurance surrender	—	25,320
Loss on sales and disposal of property and equipment	(8,078)	(6,566)
Loss on devaluation of investment in securities	(107,548)	(45,174)
Impairment loss on goodwill	(125,666)	(10,000)
Others- net	(3,027)	33,409
Other income (expenses)-net	(232,741)	22,996
Income before income taxes and minority interests	1,733,623	2,466,690
INCOME TAXES		
Current	698,104	1,027,226
Deferred	427,127	81,554
Total	1,125,232	1,108,781
MINORITY INTERESTS	47,356	64,840
NET INCOME	561,034	1,293,068

Consolidated Statements of Cash Flows

(Thousands of yen)

	Second quarter ended March 31, 2009	Second quarter ended March 31, 2010
OPERATING ACTIVITIES	911,904	926,118
INVESTING ACTIVITIES	(162,792)	(752,594)
FINANCING ACTIVITIES	(406,989)	(398,396)
EFFECT OF EXCHANGE DIFFERENCE ON CASH & CASH EQUIVALENTS	38,718	26,090
NET INCREASE IN CASH AND CASH EQUIVALENTS	303,403	(198,781)
BEGINNING OF BALANCE,CASH AND CASH EQUIVALENTS	5,638,984	6,607,331
INCREASE IN CASH AND CASH EQUIVALENTS BY MERGER OF CONSOLIDATED SUBSIDIARY	—	205,600
ENDING OF BALANCE,CASH AND CASH EQUIVALENTS	5,942,388	6,614,150

Industry Segment Information

2010 (October 1, 2009 to March 31, 2010)

(Thousands of yen)

	CRO	SMO	Preclinical Service	System Development	Total	Eliminations/ Corporate	Consolidation
SALES							
Sales to customers	11,290,014	2,040,977	405,355	780,495	14,516,843	—	14,516,843
Intersegment sales	9,621	2,265	2,070	62,265	76,222	(76,222)	—
Total	11,299,636	2,043,242	407,425	842,760	14,593,066	(76,222)	14,516,843
Operating income	2,127,371	401,704	(11,378)	(79,623)	2,438,074	5,619	2,443,694